{"cluster": 16, "subcluster": 2, "abstract_summ": "Conclusion: ACE2 levels are upregulated in some patient groups with comorbidities linked to COVID-19 and as such may have an emerging role as a circulating biomarker for severity of outcome in COVID-19.The coronavirus disease 2019 (COVID-19) pandemic is caused by a newly emerged coronavirus (CoV) called Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2).Recent studies have reported that COVID-19 has angiotensin-converting enzyme 2 (ACE2) as a functional receptor, which may lead to the development of severe cerebrovascular diseases (CVD), including strokes, in patients with risk factors for CVD such as diabetes and smoking.In this brief review, we discuss the effect of ACE inhibitor-induced bradykinin on the cardiovascular system, on the renin\u2013angiotensin\u2013aldosterone system (RAAS) regulation in COVID-19 patients, and analyze recent clinical studies regarding patients treated with RAAS inhibitors.This study demonstrates that ACE2 expression is increased in ischemic brains and vessels exposed to diabetes or smoking, makes them vulnerable to COVID-19 infection.The use of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor type 1 blockers (ARBs) improve CVD outcomes; however, there is concern that they may worsen the prognosis of CVD patients that become infected with SARS-CoV-2 because the virus uses the ACE2 receptor to bind to and subsequently infect host cells.", "title_summ": "Calcium channel blocker amlodipine besylate is associated with reduced case fatality rate of COVID-19 patients with hypertensionACE2 levels are altered in comorbidities linked to severe outcome in COVID-19Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbiditiesCOvid MEdicaTion (COMET) study: protocol for a cohort studyAltered COVID-19 receptor ACE2 expression in a higher risk group for cerebrovascular disease and ischemic strokeOutcomes in Patients with COVID-19 Infection Taking ACEI/ARBPros and cons for use of statins in people with coronavirus disease-19 (COVID-19)Overview of Covid-19 regarding the cardiovascular situation in the light of current reports.", "title_abstract_phrases": "Conclusion: ACE2 levels are upregulated in some patient groups with comorbidities linked to COVID-19 and as such may have an emerging role as a circulating biomarker for severity of outcome in COVID-19.Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbiditiesThe coronavirus disease 2019 (COVID-19) pandemic is caused by a newly emerged coronavirus (CoV) called Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2).Results from this study suggest that CCB administration for COVID-19 patients with hypertension as the comorbidity might improve the disease outcome.Outcomes in Patients with COVID-19 Infection Taking ACEI/ARBPURPOSE OF REVIEW: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus responsible for the aggressive coronavirus disease (COVID-19) pandemic.These results will enable more rational choices for randomised controlled trials for preventive and therapeutic strategies in COVID-19.Altered COVID-19 receptor ACE2 expression in a higher risk group for cerebrovascular disease and ischemic strokeCoronavirus disease 2019 (COVID-19) is a worldwide pandemic.In this brief review, we discuss the effect of ACE inhibitor-induced bradykinin on the cardiovascular system, on the renin\u2013angiotensin\u2013aldosterone system (RAAS) regulation in COVID-19 patients, and analyze recent clinical studies regarding patients treated with RAAS inhibitors."}